Aspire Private Capital’s Champions Oncology CSBR Stock Holding History

Aspire Private Capital’s Portfolio CSBR Stock Details CSBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-200	Closed	-$2K	–	287
2019 Q4	$2K	Hold	200	–	–	﹤0.01%	369
2019 Q3	$1K	Sell	200 -222	-53%	-$1.44K	﹤0.01%	396
2019 Q2	$3K	Sell	422 -243	-37%	-$2.13K	﹤0.01%	355
2019 Q1	$7K	Hold	665	–	–	﹤0.01%	339
2018 Q4	$5K	Buy	+665	New	+$7.64K	﹤0.01%	339

Other funds holding CSBR

BPI

Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

CCM

Cadence Capital Management Boston, Massachusetts $415M AUM 11.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Aspire Private Capital's CSBR Position: Q1 2020 in Review

Aspire Private Capital sold out of Champions Oncology (CSBR) in Q1 2020, closing a stake of 200 shares — an estimated $2K sold.

Aspire Private Capital first reported a position in CSBR in Q4 2018 and held it in 5 quarters. The position peaked at $7K in Q1 2019. 32 funds tracked by Wall St. Rank hold CSBR as of Q1 2020.

Aspire Private Capital reported no remaining Champions Oncology position as of Q1 2020 after selling out during the quarter.
Aspire Private Capital sold 200 Champions Oncology shares in Q1 2020, an estimated $2K.
Aspire Private Capital first reported a position in Champions Oncology in Q4 2018 and held it in 5 quarters.
Aspire Private Capital's Champions Oncology position peaked at $7K in Q1 2019.
32 funds tracked by Wall St. Rank held Champions Oncology as of Q1 2020.

Based on Aspire Private Capital's 13F filing for Q1 2020, filed 14 May 2020.